Bengalantamine effects

Bengalantamine (trade nameZunveyl), as a prescription drug, is widely used to treat Alzheimer's disease mild to moderate dementia (AD), aiming to improve patients' thinking, memory and daily activities. Its approval is based on the results of bioequivalence and tolerability studies compared with galantamine immediate-release tablets and galantamine extended-release capsules.

In multiple bioavailability studies, benzalantamine was compared with two dosage forms of galantamine (immediate-release tablets, extended-release capsules). These studies confirmed that the efficacy of benzalantamine was comparable to that of galantamine, and the incidence of gastrointestinal adverse events recorded in all studies was very low, less than 2%, and no adverse effects such as insomnia were observed. This data fully demonstrates that benzalantamine has excellent tolerability and safety while maintaining good efficacy.

Bengalantamine acts as an acetylcholinesterase inhibitor (AChEI) by preventing acetylcholine from being broken down, thereby increasing the amount of acetylcholine released between neurons in the brain. This dual mechanism of action allows benzalantamine to significantly increase acetylcholine levels in the brain, thereby improving symptoms of dementia.

Additionally, clinical trials of galantamine (bengalantamine’s active ingredient) have demonstrated sustained improvements in cognitive function and quality of life after long-term treatment. This long-term benefit makes benzalantamine an important drug option for the treatment of mild to moderate dementia in Alzheimer's disease.

In summary, benzalantamine brings new hope to patients with Alzheimer's disease due to its unique dual mechanism of action, excellent tolerability and safety, and significant effects of long-term treatment.

Reference link:https://www.drugs.com/pro/zunveyl.html#S12.3